RxDoctor Payments Data

June Kim, MD

Pulmonary Disease · Orlando, FLNPI 1144491929

Payments from drug & device makers

$1,196in general payments, 2019–2025

Across 28 payments — averaging $42.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$237
  • GSK$138
  • Insmed, Inc.$138
  • Jazz Pharmaceuticals Inc.$123
  • United Therapeutics Corporation$112
  • Johnson & Johnson$107
  • plus $340 from 9 others

What the payments were for

  • Food & beverage$1,18099%
  • Education$161%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,196 in reported general payments places this provider in the 30th percentile of 953 pulmonary disease providers in Florida.

See all pulmonary disease providers in Florida

Medicare billing

Part B allowed, 2024
$31,398
Medicare patients
85
Services billed
262

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CresembaIsavuconazonium Sulfate11$73,714
Everolimus24$45,646
EliquisApixaban18$20,681
Atovaquone32$15,934
Tacrolimus53$5,051
Hydrocortisone93$4,960
Acyclovir105$1,396
Pravastatin Sodium67$1,063
Azithromycin76$885
Mycophenolate Mofetil20$703
Gabapentin20$697
Pantoprazole Sodium35$521
Montelukast Sodium37$482
Prednisone47$450
Omeprazole27$372

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncCresemba$38$73,71411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 953 pulmonary disease providers in Florida.

Other pulmonary disease in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →